PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Riedl, T.* ; Faure-Dupuy, S.* ; Rolland, M.* ; Schuehle, S.* ; Hizir, Z.* ; Calderazzo, S.* ; Zhuang, X.* ; Wettengel, J.M. ; Lopez, M.A.* ; Barnault, R.* ; Mirakaj, V.* ; Prokosch, S.* ; Heide, D.* ; Leuchtenbergeg, C.* ; Schneider, M.* ; Heßling, B.* ; Stottmeier, B.* ; Wessbecher, I.M.* ; Schirmacher, P.* ; McKeating, J.A.* ; Protzer, U. ; Durantel, D.* ; Lucifora, J.* ; Dejardin, E.* ; Heikenwalder, M.*

HIF1α-mediated RelB/APOBEC3B downregulation allows Hepatitis B Virus persistence.

Hepatology 74, 1766-1781 (2021)
Verlagsversion Postprint Forschungsdaten DOI PMC
Open Access Gold
New therapeutic strategies against Hepatitis B virus (HBV) focus, among others, on the activation of the immune system to enable the infected host to eliminate HBV. Hypoxia inducible factor 1 alpha (HIF1α) stabilisation has been associated with impaired immune responses. HBV pathogenesis triggers chronic hepatitis-related scaring, leading inter alia to modulation of liver oxygenation and transient immune activation, both factors playing a role in HIF1α stabilisation. We addressed whether HIF1α interferes with immune-mediated induction of the cytidine deaminase APOBEC3B and subsequent covalently closed circular DNA (cccDNA) decay. Liver biopsies of chronic HBV patients (CHB) were analysed by IHC, and in situ hybridization. The effect of HIF1α induction/stabilisation on differentiated HepaRG or mice +/- HBV +/- LTβR-agonist (BS1) was assessed in vitro and in vivo. Induction of A3B and subsequent effects were analysed by RT-qPCR, immunoblotting, ChIP, ICC, and mass-spectrometry. Analysing CHB highlighted that areas with high HIF1α levels and low A3B expression correlated with high HBcAg, potentially representing a reservoir for HBV survival in immune-active patients. In vitro, HIF1α stabilisation, strongly impaired A3B expression and anti-HBV effect. Interestingly, HIF1α knock-down was sufficient to rescue the inhibition of A3B-upregulation and -mediated antiviral effects, whereas HIF2α knock-down had no effect. HIF1α stabilisation decreased the level of RelB protein but not its mRNA, which was confirmed in vivo. Noteworthy, this function of HIF1α was independent of its partner ARNT. In conclusion, inhibiting HIF1α expression or stabilisation represents a novel anti-HBV strategy in the context of immune-mediated A3B induction. High HIF1α, mediated by hypoxia or inflammation, offers a reservoir for HBV survival in vivo, and should be considered as a restricting factor in the development of novel immune therapies.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
17.425
0.000
10
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Hif1α ; Hepatitis B Virus ; Nf-κb ; Cccdna ; Reservoir; Nf-kappa-b; Expression; Infection; Pathway
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 0270-9139
e-ISSN 1527-3350
Zeitschrift Hepatology
Quellenangaben Band: 74, Heft: 4, Seiten: 1766-1781 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort Hoboken, NJ
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Virology (VIRO)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-502700-003
Förderungen Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China
Deutsche Forschungsgemeinschaft (DFG; German Research Foundation)
ERC CoG (HepatoMetabopath)
ERC POC
Helmholtz Future topic Inflammation and Immunology
Zukunftssthema 'Immunology and Inflammation'
Rainer Hoenig Stiftung
FNRS/FWO under EOS
FSR
Fondation Leon Fredericq of the University of Liege
FP7-Infect-Era grant
INSERM (Institut National de la Sante et de la Recherche Medicale)
ANRS (Agence Nationale de Recherche sur le Sida et les hepatites virales)
EU-Infect Era
Wellcome Trust
MRC
European Union
DOI 10.1002/hep.31902
WOS ID WOS:000684936800001
Scopus ID 85112391880
PubMed ID 33991110
Erfassungsdatum 2021-06-21
[➜Korrektur melden]